CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
复发/难治性多发性骨髓瘤 CAR-T 细胞治疗后重症 SARS-CoV-2 感染及继发真菌感染：一场艰难而结局圆满的抗争
英文原题：Severe SARS-CoV-2 and subsequent fungal infections after CAR T-cell therapy for relapsed/refractory multiple myeloma: a challenging and happy ending fight.
查看英文原题
Severe SARS-CoV-2 and subsequent fungal infections after CAR T-cell therapy for relapsed/refractory multiple myeloma: a challenging and happy ending fight.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
嵌合抗原受体（CAR）T细胞为复发/难治性多发性骨髓瘤（R/R MM）带来了有前景的治疗前景。然而，细胞疗法、既往治疗以及MM本身所致的免疫功能受损都可能促进感染发生。R/R MM患者往往对SARS-CoV-2疫苗应答欠佳，COVID-19可能在这类患者中发展为危及生命的感染。本文报告一例R/R MM患者接受CAR-T 细胞治疗后发生严重且迁延的COVID-19肺炎，需要复杂临床管理。对于接受CAR-T 治疗的MM患者，应考虑长期感染并发症，因为此类并发症可能抵消这项新疗法的疗效。
展开英文摘要原文
Chimeric antigen receptor (CAR) T-cells have unveiled a promising therapeutic horizon for relapsed/refractory multiple myeloma (R/R MM). Nevertheless, immune impairment induced by cellular therapies, previous treatments and MM itself could promote infectious events. COVID-19 could evolve into a life-threating infection in R/R MM patients who often have suboptimal responses to SARS-CoV-2 vaccines.
Here, we describe a case of severe and long-lasting COVID-19 pneumonia after CAR T-cell therapy for R/R MM requiring a complex clinical management. Long-term infectious complications in MM patients undergoing CAR T-cells should be taken into consideration as they could counteract the efficacy of this new treatment.
论文信息
- 作者
- Ielo C、Fazio F、Rocchi S、Rizzello I、Mancuso K、Zamagni E、Cavo M、Petrucci MT
- 单位
- Hematology Unit, Department of Translational and Precision Medicine, Azienda Policlinico Umberto I, Sapienza University of Rome, Italy.Italy
- 文献类型
- 病例报告
- 期刊
- Leukemia research reports2024
- 原文标识
- PubMed 38078287 · DOI 10.1016/j.lrr.2023.100399
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →